However, knockdown of ADAM17 or treatment with anti-ADAM17 antibody MEDI3622 resulted in regression of pancreatic tumors, accompanied by down-regulated EGFR/STAT3 signaling, increased cytotoxic T cells, and decreased granulocyte-like medullary inhibitory cells in mouse models of pancreatic cancer (212). The gene discussed is ADAM17; the disease is familial pancreatic carcinoma.